Related Experiment Video

Updated: Mar 7, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure

Jasmine A Luzum1,2, Kevin M Sweet3, Philip F Binkley4

  • 1Center for Pharmacogenomics, Ohio State University College of Medicine, Columbus, Ohio, USA. jluzum@umich.edu.

Pharmaceutical Research
|February 10, 2017
PubMed

Insights

The CYP2D6*4 gene variant impacts beta-blocker doses in heart failure patients. Carriers required lower metoprolol doses and showed a trend for higher carvedilol doses, suggesting CYP2D6*4 as a potential biomarker.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Drug Metabolism

Background:

  • Heart failure management often involves beta-blockers.
  • Individual variability in drug response necessitates personalized treatment approaches.
  • Cytochrome P450 2D6 (CYP2D6) plays a crucial role in metabolizing various drugs, including some beta-blockers.

Purpose of the Study:

  • To investigate the association between the CYP2D6*4 polymorphism and the maintenance dose of beta-blockers (carvedilol and metoprolol) in patients with heart failure.
  • To determine if CYP2D6*4 influences the dosage requirements for carvedilol and metoprolol.

Main Methods:

  • Retrospective chart review of heart failure patients.
  • Logistic regression modeling was used to analyze the association between CYP2D6*4 genotype and beta-blocker maintenance dose.
  • Study included 65 patients on carvedilol and 33 patients on metoprolol, with demographic data on sex and ethnicity.

Main Results:

  • CYP2D6*4 polymorphism was significantly associated with a lower maintenance dose of metoprolol (OR 0.13, p=0.023).
  • A trend indicated an association between CYP2D6*4 and a higher maintenance dose of carvedilol (OR 2.94, p=0.093).
  • No patients with the CYP2D6*4 variant achieved the target metoprolol dose of 200 mg/day.

Conclusions:

  • The CYP2D6*4 genotype is linked to reduced tolerated maintenance doses of metoprolol, consistent with CYP2D6's role in its metabolism.
  • The tolerated maintenance dose of carvedilol may be higher in CYP2D6*4 carriers, aligning with CYP2D6's role in its activation.
  • CYP2D6*4 warrants further investigation as a predictive biomarker for optimizing beta-blocker therapy in heart failure patients.
Abstract

Keywords:
CYP2D6beta-blocker dosecarvedilolheart failuremetoprololpharmacogenetics

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
77
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
79
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
67